Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.2B | $92M | $2M | $69M | 0.2% | 6.5% | -83.6% |
| 2024 | $1.1B | $90M | $13M | $135M | 1.0% | -3.0% | -161.5% |
| 2023 | $1.1B | $61M | $-20M | $126M | -1.7% | -11.5% | -460.7% |
| 2022 | $1.3B | $97M | $6M | $17M | 0.5% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 1,295.95 | 1,147.11 | 1,112.24 | 1,184.84 |
| Operating Revenue | - | 1,295.95 | 1,147.11 | 1,112.24 | 1,184.84 |
| Cost Of Revenue | - | 706.96 | 650.27 | 641.24 | 681.40 |
| Gross Profit | - | 588.99 | 496.84 | 471 | 503.44 |
| Operating Expense | - | 591.31 | 531.71 | 470.67 | 498.28 |
| Research And Development | - | 104.97 | 97.12 | 90.41 | 88.67 |
| Selling General And Administration | - | 486.34 | 434.59 | 380.25 | 409.61 |
| Total Expenses | - | 1,298.27 | 1,181.98 | 1,111.90 | 1,179.68 |
| Operating Income | - | -2.32 | -34.87 | 0.34 | 5.16 |
| Total Operating Income As Reported | - | -2.32 | -34.87 | 0.34 | 5.16 |
| EBITDA | - | 96.85 | 60.69 | 90.09 | 91.79 |
| Normalized EBITDA | - | 96.85 | 60.69 | 90.09 | 91.79 |
| EBIT | - | -2.32 | -34.87 | 0.34 | 5.16 |
| Net Interest Income | - | -0.13 | 14.76 | 25.26 | 6.16 |
| Net Non Operating Interest Income Expense | - | -0.13 | 14.76 | 25.26 | 6.16 |
| Pretax Income | - | -2.45 | -20.11 | 25.59 | 11.32 |
| Tax Provision | - | -8.10 | 0.26 | 13.06 | 9.27 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | 5.65 | -20.37 | 12.53 | 2.05 |
| Net Income From Continuing And Discontinued Operation | - | 5.65 | -20.37 | 12.53 | 2.05 |
| Net Income From Continuing Operation Net Minority Interest | - | 5.65 | -20.37 | 12.53 | 2.05 |
| Net Income | - | 5.65 | -20.37 | 12.53 | 2.05 |
| Net Income Common Stockholders | - | 5.65 | -20.37 | 12.53 | 2.05 |
| Net Income Including Noncontrolling Interests | - | 5.65 | -20.37 | 12.53 | 2.05 |
| Normalized Income | - | 5.65 | -20.37 | 12.53 | 2.05 |
| Diluted NI Availto Com Stockholders | - | 5.65 | -20.37 | 12.53 | 2.05 |
| Basic Average Shares | - | 44.40 | 45.21 | 46.05 | 45.96 |
| Diluted Average Shares | - | 45.89 | 45.21 | 46.26 | 46.36 |
| Reconciled Depreciation | - | 99.17 | 95.56 | 89.76 | 86.63 |
| Reconciled Cost Of Revenue | - | 706.96 | 650.27 | 641.24 | 681.40 |
| Total Other Finance Cost | - | 0.13 | -14.76 | -25.26 | -6.16 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Omnicell, Inc.this co. | OMCL | $2.0B | 967.26 | 1.61 | 0.2% | 21.53 |
| NovoCure Limited | NVCR | $2.1B | - | 6.12 | -40.0% | - |
| Intellia Therapeutics, Inc. | NTLA | $2.1B | - | 3.07 | -61.5% | - |
| Recursion Pharmaceuticals, Inc. | RXRX | $2.0B | -3.13 | 1.78 | -57.0% | -2.42 |
| Progyny, Inc. | PGNY | $2.0B | 34.11 | 3.87 |
| - |
| - |
| - |
| - |
| 11.3% |
| 21.18 |
| Trevi Therapeutics, Inc. | TRVI | $2.0B | -46.25 | 10.79 | -23.3% | -45.92 |
| Iovance Biotherapeutics, Inc. | IOVA | $2.0B | -5.00 | 2.80 | -56.0% | -5.25 |
| Ocular Therapeutix, Inc. | OCUL | $1.9B | -7.25 | 2.94 | -40.6% | -5.07 |
| Harmony Biosciences Holdings, Inc. | HRMY | $1.9B | 12.02 | 2.19 | 18.2% | 5.17 |
| Peer Median | - | -4.07 | 3.01 | -40.3% | -3.74 | |